DNA Damage Is a Potential Marker for TP53 Mutation in Colorectal Carcinogenesis

被引:0
|
作者
Scalise J.R. [1 ]
Poças R.C.G. [1 ]
Caneloi T.P. [2 ]
Lopes C.O. [2 ]
Kanno D.T. [2 ]
Marques M.G. [2 ]
Valdivia J.C.M. [2 ]
Maximo F.R. [2 ]
Pereira J.A. [3 ]
Ribeiro M.L. [1 ]
Priolli D.G. [1 ,4 ]
机构
[1] Postgraduate Programme Strictu Senso in Health Science, Sao Francisco University Medical School, Sao Paulo
[2] Scientific Initiation Student, Scientific Initiation Programme, Sao Francisco University Medical School, Sao Paulo
[3] Department of Pathology, Sao Francisco University Medical School, Sao Paulo
[4] Rua São Vicente 614. Jardim Paulista, Atibaia, CEP: 12947-390, SP
基金
巴西圣保罗研究基金会;
关键词
Adenocarcinoma; Adenoma; DNA damage; Immunohistochemistry; Tumor suppressor protein p53;
D O I
10.1007/s12029-016-9846-0
中图分类号
学科分类号
摘要
Purpose: The ability to measure oxidative DNA damage in a tissue allows establishment of the relationship between DNA damage and mutations in normal and neoplastic cells. It is well known that TP53 is a key inhibitor of tumor development and preserves the genome integrity in each cell. The aim of the present study was to investigate the relationship between DNA damage and TP53 mutation in colorectal adenoma and adenocarcinoma, and the value of DNA damage as potential marker of TP53 mutation in non-tumor tissues adjacent to colon malignant lesions. Methods: Tissue samples were obtained by colonoscopy from patients with adenoma and/or adenocarcinoma and from healthy volunteers. Diagnosis was defined by histopathology. Immunohistochemistry with computer-assisted image analysis was performed to quantify TP53 mutation. Oxidative DNA damage was determined by comet assay. Statistical analyses were performed with 5 % of significance level. Results: The TP53 level was higher in non-tumor tissues from tumor patients than in normal tissues from healthy volunteers (p = 0.01). Likewise, higher TP53 levels were observed in tumor tissues compared with the non-tumor tissues (p = 0.00). Oxidative DNA damage levels were higher in tumor tissues than in non-tumor tissues (p = 0.00). The amount of TP53 (p = 0.00) and oxidative DNA damage (p = 0.00) in normal and tumor tissue was related. The relationship between oxidative DNA damage and TP53 mutation was demonstrated in all samples (p = 0.00). Conclusion: Oxidative DNA damage is an intervening variable for TP53 mutation in colorectal adenoma-carcinoma. Our data suggests that oxidative DNA damage is a potential marker of TP53 mutation in colorectal carcinogenesis. © 2016, Springer Science+Business Media New York.
引用
收藏
页码:409 / 416
页数:7
相关论文
共 50 条
  • [31] Clinical significance of TP53 mutation in myeloma
    W J Chng
    T Price-Troska
    N Gonzalez-Paz
    S Van Wier
    S Jacobus
    E Blood
    K Henderson
    M Oken
    B Van Ness
    P Greipp
    S V Rajkumar
    R Fonseca
    Leukemia, 2007, 21 : 582 - 584
  • [32] TP53 protein expression in colorectal cancer
    Ben Ayed, I.
    Ben Nasr, S.
    Jaballah-Gabteni, A.
    Yaiche, H.
    Ben Jemii, N.
    Wider, D.
    Laasili, T.
    Boubaker, S.
    Haddauoi, A.
    Tounsi-Kettiti, H. Guettiti
    ANNALS OF ONCOLOGY, 2023, 34 : S148 - S148
  • [33] Expression evaluation of TP53 in colorectal cancer
    Oliveira, Ligia Petrolini
    Lopez, Ignacio
    Tucci, Paula
    Marin, Monica
    Coudry, Renata de Almeida
    CANCER RESEARCH, 2011, 71
  • [34] The role of TP53 mutation status in the response to DNA methyltransferase inhibitor treatment
    Omar, Khadra K.
    Grundy, Erin E.
    Cox, Olivia
    Hadley, Melissa
    Chiappinelli, Katherine B.
    CANCER RESEARCH, 2023, 83 (07)
  • [35] A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA
    Gemignani, F
    Moreno, V
    Landi, S
    Moullan, N
    Chabrier, A
    Gutiérrez-Enríquez, S
    Hall, J
    Guino, E
    Peinado, MA
    Capella, G
    Canzian, F
    ONCOGENE, 2004, 23 (10) : 1954 - 1956
  • [36] A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA
    Federica Gemignani
    Victor Moreno
    Stefano Landi
    Norman Moullan
    Amélie Chabrier
    Sara Gutiérrez-Enríquez
    Janet Hall
    Elisabeth Guino
    Miguel Angel Peinado
    Gabriel Capella
    Federico Canzian
    Oncogene, 2004, 23 : 1954 - 1956
  • [37] TP53 Mutation by CRISPR System Enhances the Malignant Potential of Colon Cancer
    Watanabe, Sho
    Tsuchiya, Kiichiro
    Nishimura, Ryu
    Shirasaki, Tomoaki
    Katsukura, Nobuhiro
    Hibiya, Shuji
    Okamoto, Ryuichi
    Nakamura, Tetsuya
    Watanabe, Mamoru
    MOLECULAR CANCER RESEARCH, 2019, 17 (07) : 1459 - 1467
  • [38] Combining TP53 mutation and isoform has the potential to improve clinical practice
    Das, Sankalita Ray
    Delahunt, Brett
    Lasham, Annette
    Lu, Kunyu
    Wright, Deborah
    Print, Cristin
    Slatter, Tania
    Braithwaite, Antony
    Mehta, Sunali
    PATHOLOGY, 2024, 56 (04) : 473 - 483
  • [39] Harmonized microarray/mutation scanning analysis of TP53 mutations in undissected colorectal tumors
    Favis, R
    Huang, JM
    Gerry, NR
    Culliford, A
    Paty, P
    Soussi, T
    Barany, F
    HUMAN MUTATION, 2004, 24 (01) : 63 - 75
  • [40] TP53 mutation is enriched in colorectal cancer liver metastasis in the context of polyclonal seeding
    Sun, Wenjie
    Sun, Qingrong
    Zhong, Anjing
    Lyne, Anne-Marie
    Huang, Dongdong
    Han, Fengyan
    Lai, Maode
    Zhang, Honghe
    PATHOLOGY RESEARCH AND PRACTICE, 2022, 236